Stroke Trial, Recruiting NCT06057129 Sponsor: Swiss Federal Institute of Technology Condition: Stroke
Back to Stroke

Stroke Trial, Recruiting

NCT06057129
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 90 years old (male or female)
  • People who have had a stroke recently — specifically, those who can be enrolled within 12 weeks of the stroke happening
  • People who were largely independent before their stroke (with little or no disability beforehand)
  • People who have at least some difficulty with movement, sensation, or coordination as a result of their stroke, based on a standard medical assessment
  • People whose home has enough space to set up a piece of rehabilitation equipment called the ReHandyBot

Who may not be able to join:

  • People with significant muscle stiffness or spasticity in the shoulder, forearm, elbow, wrist, or fingers, above a certain level measured by a standard scale
  • People with moderate to severe difficulties with language and communication (aphasia), as assessed by a standard test
  • People with moderate to severe cognitive (thinking and memory) difficulties, as measured by a standard assessment
  • People whose arm was already affected by another condition before the stroke
  • People experiencing severe pain in the affected arm (rated 5 or above on a standard pain scale)
  • People with other medical conditions that could interfere with the study (confirm with trial site)
  • People with a pacemaker or any other active medical implant
  • People who will be moving to a care home or assisted living facility after leaving hospital

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paolo Rossi, Dr. med., Clinica Hildebrand Brissago

Phone: +41 44 510 72 31

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Swiss Federal Institute of Technology
Registry
ClinicalTrials.gov
Start date
13 November 2023
Est. completion
1 April 2026

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Dose of unsupervised therapy - Minutes; Dose of unsupervised therapy - Repetitions; Dose of unsupervised therapy - Percentual change in therapy time

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov